ClinicalTrials.gg
RecruitingNCT05905419OPALUpdated Jun 3, 2026

Neuroimaging of Opioid Phase (OPAL)

An interventional study of Opioid Phase in Chronic Pain and Opioid Use, sponsored by Duke University. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Duke University · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Chronic Pain by Duke University — 5 open to participants now, 5 under way, none of them phase 3. Chronic Pain · Duke University.

Planned enrollment
6th of 16
140 · median 99
Started
2023
the only one that year
No phase
14 of 19
5 open now
Registered
13th of 19
by date

Among the 19 studies in Chronic Pain by Duke University, this one is the 6th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2023, is one of 14 with no phase, and was the 13th registered.

Chronic Pain

3,230 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.

Browse Chronic Pain studies →

Open to participants now

5 of the 19 studies in Chronic Pain by Duke University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Chronic Pain by Duke University, or all of them as a file.
02

Study summary

The purpose of this study is to compare activity in the brains of female adults with chronic pain and/or opioid use, and healthy female adults that may help to develop new and targeted treatments for adults with chronic pain and alternatives to opioid therapy.

Read the detailed description

The objective of the study is to determine differences in neurophysiology and behavior during different phases of opioid use in patients. Study activities will include neuroimaging (MRI and fMRI), behavioral tasks, sensory testing, blood draws, and questionnaires. The neuroimaging data will be analyzed using specialized software; data from questionnaires, sensory testing, and behavioral task performance will be analyzed using standard statistical software. Risks and safety concerns include standard, minimal risks associated with MRI scans, sensory testing, blood draws, and confidentiality.

03

Conditions studied

  • Chronic Pain
  • Opioid Use

Keywords

  • fibromyalgia
  • women
  • brain
  • functional MRI
  • opioid
  • opiate
  • narcotic
  • chronic pain
  • pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. female and ages 18+
  2. ability to read/understand English and give consent to participate
  3. no current or history of chronic pain
  4. not regularly taking any pain-relieving or mood-altering medications (per PI discretion)
  5. absence of use of opioid medications

Inclusion Criteria for Individuals with Chronic Pain:

  1. female and ages 18 +
  2. ability to read/understand English and give consent to participate
  3. self-reported or physician diagnosis of fibromyalgia and/or chronic pain
  4. current use of opioid medication(s) for inclusion in the opioid patient group -OR- absence of use of opioid medications for inclusion in the non-opioid patient group

Exclusion criteria

Exclusion Criteria (for both groups):

  1. limited ability to participate fully in behavioral tasks, longitudinal follow-up
  2. MRI
  3. any factors that at the discretion of the investigators would adversely affect the participant or the integrity of the study
  4. male
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Female adults with chronic pain who take prescribed opioid medications

    Opioid taking participants will undergo two study visits, one for each opioid phase ("peak" or "trough")

    Other: Opioid Phase

  • No intervention
    Female adults with chronic pain who do not take opioid medications

    Participants with chronic pain who are not taking opioids will undergo one study visit

  • No intervention
    Healthy controls

    Healthy female participants who are not taking opioids will undergo one study visit

Interventions

  • OtherOpioid Phase

    Opioid-taking patients are assigned to take their prescribed opioid medication before ("peak" opioid phase) during 1 scan and after ("trough" opioid phase) during the other MRI scan

06

What researchers measure

Primary outcomes

  1. Characterize brain fMRI-based activity related to neurobiological consequences of opioid therapy

    Compare brain fMRI-based response to reward stimuli during a monetary incentive delay (MID) task and functional connectivity of brain reward circuitry during resting state.

    Time frame: During study visits up to 4 weeks apart

Secondary outcomes

  1. Characterize spinal cord fMRI-based activity related to neurobiological consequences of opioid therapy

    Compare spinal cord fMRI-based response and resting-state functional connectivity.

    Time frame: During study visits up to 4 weeks apart

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Jun 2027, 48 months after the start.

Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 48 months is above that.

Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2023
First posted
Jun 15, 2023
StartActual
Jun 1, 2023
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2027
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05905419
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Jun 15, 2023
Start date
Jun 1, 2023
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Jun 3, 2026

Study contacts

HAPN Lab Manager
Contact
chronicpainresearch@duke.edu
919-684-2758
Angelina Xiong, BS
Contact
angelina.xiong@duke.edu
919-684-3136
Katherine T Martucci, PhD
principal investigator · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion